07 December 2023: Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz 1ACDEF* , Anna Dańska-Bidzińska 2ABDEG , Małgorzata Fuksiewicz 1BCDE , Anna Nasierowska-Guttmejer 3BC , Dorota Raczkiewicz 4C , Mariusz Gujski 5BEF , Szymon Piątek 6B , Mariusz Bidziński 6AEGDOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 3 Serum concentrations of biomarkers in healthy subjects as controls and in uterine sarcoma patients.
| Parameter | Cut off value 95° | Control group (n=40) | Patients (n=52) | P | AUC |
|---|---|---|---|---|---|
| Median (range) | Median (range) | ||||
| CA 125 IU/mL | 35 | 10.7 (2.8–31.5) | 16.7 (7.0–341) | 0.0001 | 0.740 |
| IL-8 pg/mL | 12,5 | 10 (10–12,5) | 14.2 (4.0–308) | 0.0029 | 0.676 |
| VEGF pg/mL | 325 | 91 (9–331) | 398 (96–2000) | 0.0001 | 0.905 |
| sFTL1 pg/mL | 482 | 384 (286–495) | 2235 (53–420) | 0.0010 | 0.705 |
| VEGF R2 pg/mL pg/mL | 11832 | 9594 (7138–12363) | 11172 (6699–14703) | 0.0010 | 0.705 |
| sTNFRI pg/mL | 175 | 852 (604–1200) | 1716 (1154–5000) | 0.0001 | 0.998 |
| MMP-9 ng/mL | 734 | 411 (16–719) | 599 (156–3379) | 0.0003 | 0.704 |